Post -contrast Three -dimensional MP RAGE T1WI Sequence Compared to Brain MRV Sequence for Diagnosing Brain Sinus Venous Thrombosis.

Background: Dural sinus thrombosis is considered as a one of the clinical and radiological emergencies that require special attention and high index of suspicion and needs combined effort of both the treating physician and the radiologist to obtain proper diagnosis and subsequently proper management.

Objective: The aim of this article was to compare the accuracy of MRV TOF and post contrast MP-RAGE sequences in diagnosis of cerebral sinus venous thrombosis.

Methods: After all informed consents were obtained and upon ethical committee approval from the ethical committee in Joradanian Royal medical services in Amman we perform this study as a retrospective study done on 50 patients with cerebral sinus venous thrombosis with 50 pateints control group done at king Hussein medical center in Amman Jordan.

Castigating intraoperative bleeding: Tranexamic acid, a new ally.

Introduction: The field of instrumented spinal procedures is associated with substantial blood volume losses, which is one of the major hazards we encounter; this would lead to a greater need for blood products transfusions. The frequent use of these products can have negative consequences due to body fluid shifting, and donor-host rejection. Thus, it has become mandatory to establish strategies to maintain blood volume and minimize losses.

Infantile Extracranial Rhabdoid Tumor of the Scalp.

Extracranial rhabdoid tumor is a rare tumor that can originate in multiple organs, and it is most commonly seen in the kidneys. This tumor has a grave prognosis. We report to the best of our knowledge the first case of infantile scalp extracranial rhabdoid tumor in a 6-month-old male baby who presented with a right parietal scalp mass since the age of 1 month.

Delving Inside the Enigmatic Central Neurocytoma: Electronic Hospital Database Retrieval.

Introduction: Central neurocytomas (CNCs) appear as a rare benign intraventricular lesions involving <0.5% of primary brain tumors. There are no consensus guidelines for the optimal management strategy, so that this entity still enigmatic.